IMUC
EOM Pharmaceuticals Holdings, Inc.0.1790
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
22.64MP/E (TTM)
0.02Basic EPS (TTM)
9.94Dividend Yield
0%Recent Filings
8-K
NYSE delisting notice issued
ImmunoCellular Therapeutics received NYSE American notice on October 16, 2018, to delist its common stock and warrants due to abnormally low trading price; trading suspended immediately. The company opted against review and expects OTC Markets quotation post-SEC procedures. Delisting signals liquidity squeeze.
8-K
Delists from NYSE American
ImmunoCellular Therapeutics' board opted to delist common stock and warrants from NYSE American on October 10, 2018, citing insurmountable financial woes and NYSE non-compliance despite a compliance plan until December 23. CEO Gringeri, CFO Fractor, and SVP Swanson resigned effective October 15, shifting to consultants. Delisting hits November 5; stock eyes OTC. Liquidity tanks.
8-K
Q2 loss plunges 97%
ImmunoCellular slashed Q2 operating loss 97% to $307K versus prior year, ending with $2.9M cash, no debt. Progressed Stem-to-T-Cell program by verifying T-cell receptor transfer into stem cells for upcoming preclinical tests; exploring mergers or asset sales. Settled class action for $1.15M, fully insured. Cash burn continues.
10-Q
Q2 FY2018 results
ImmunoCellular Therapeutics posted a Q2 net loss of $0.3M, far better than $4.1M y/y, thanks to slashed R&D from $10.4M to $59K after suspending the ICT-107 phase 3 trial. Cash burned $3.8M YTD, leaving $2.9M at June 30, 2018, with no debt but going concern warnings. Expenses dropped sharply; legal fee recovery added $0.4M credit. Cash runway short. Stem-to-T cell work continues slowly. Ongoing securities litigation hangs over.
8-K
Q1 loss shrinks to $1M
ImmunoCellular Therapeutics reported Q1 2018 net loss of $1.0 million ($0.02/share), down sharply from $5.9 million ($1.67/share) a year ago, thanks to halted ICT-107 trial and slashed R&D. Cash burned $1.6 million, leaving $5 million on hand while current liabilities dropped nearly $900,000. Progress hit in Stem-to-T-Cell program. They're shopping for a sale or merger.
HCWB
HCW Biologics Inc.
1.78-0.09
IMA
ImageneBio, Inc.
6.25+0.08
IMCR
Immunocore Holdings plc
36.21+0.19
IMNM
Immunome, Inc.
23.48+0.84
IMTX
Immatics N.V.
10.09+0.11
IMUX
Immunic, Inc.
0.60-0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
OCS
Oculis Holding AG
19.84-0.63